What's on @ CIOMS

COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES

WWW.CIOMS.CH June 2017 | **Newsletter #** **18**

CIOMS LAUNCHES NEW WEBSITE

After several months of work with our website designers Inslab, CIOMS is pleased to announce the launch of its new website.

In addition to the online bookshop which allows payment by credit card, the website has many new features including:

- Readability on smartphones and tablets
- Instant access from Working Group pages to their publications
- Membership area with login for CIOMS members giving access to documents and allowing for annual fees to be paid online
- Expanded history of CIOMS linking to its many publications
- More information about CIOMS areas of work
- Availability of some older CIOMS publications
- CIOMS in the media

HIGHLIGHTS

- CIOMS launches new website
- CIOMS Working Group on Drug Induced Liver Injury
- Earlier publications available again



NEW CIOMS WORKING GROUP

CIOMS' new Working Group on Drug- Induced Liver Injury (DILI) was launched with the first meeting taking place 27–28 April 2017 in Geneva. The working group is composed of more than 30 representatives of academia, industry and regulators from Asia, Africa, Europe and America.

The scope of the CIOMS working group on DILI is to establish a global perspective on liver signal detection, assessment, and risk management in drug development and post-marketing. The first in person meeting had the following objectives:

- Identify key challenges to focus on
- Develop WG business plan
- Set up subgroups to address key topics
- Identify other key DILI initiatives to interact with

During the introductory session it was decided that the DILI WG will be chaired by Hervé Le Louet, with Raul Andrade and Arie Regev acting as co-chairs. Maribel Lucena and Michael Merz were suggested as rapporteurs of the group.
Short introductory presentations on CIOMS, academic, industry, and regulatory perspective were made by Hervé Le Louet, Raul Andrade, Arie Regev, and Mark Avigan.

Key discussion points included the following:

- What are adequate criteria for DILI case definition, characterization and classification of phenotypic subgroups in DILI?
- Are herbal and dietary supplements within or out of scope?
- Gaps and challenges with data collection and causality assessment pre and post marketing
- Best practices for data ascertainment, management, and analysis
- Utilization of new liver safety biomarkers
- Proper communication of DILI risk to patients and prescribers
- Adequate risk management and risk minimization

Accordingly, three subgroups were agreed upon, each with contribution from industry, academia, and regulatory agencies:

Group 1: Principles in Detection, Characterization and Risk Assessment of DILI in Clinical Trials and Post Marketing
Chairs: Arie Regev *(Eli Lilly),* Raul Andrade *(University of Malaga)*
Members: Mari Thörn, Hajime Takikawa, Raul J Andrade, Arie Regev, Mark Avigan, Daisuke Tanaka, Jean- Marc Vidal

Group 2: Liver Safety Biomarkers: Recommended strategies for pre-marketing and post-marketing studies and efforts
Chairs: Bob Fontana *(University of Michigan),* Michael Merz *(Novartis)*
Members: Bob Fontana, Amel Benkritly, James Southern, Javier Waksman, Michael Merz, Maribel Lucena

Group 3: DILI risk stratification, minimization, and communication
Chair: Einar Björnsson *(National University Hospital of Iceland)*
Members: Hui-Talia Zhang, Einar Björnsson, Shinobu Uzu, Michele Bortolini, Haibo Song

The breakout sessions of the three subgroups followed. All groups had rich discussions and made good progress in defining the work plans for the groups.

During final discussions with all WG members it was decided that the next face-to-face meeting should be around October. Maribel Lucena and Raul Andrade suggested hosting the meeting in Malaga, on 14–15 November. By then, an early draft of the report should be available. Subgroup chairs will lead compilation of the draft. The core document should focus on robust recommendations. Perspectives more bound to change over time should go in appendices. It was also noted that the recommendations in the report will not have a binding character, but will reflect consensus opinion of the CIOMS DILI group. The expected audience of the paper will be public stakeholders, regulatory bodies, investigators and practitioners.

ICH meets for the first time in Canada

Due to an opening up and enlargement of the International Council for Harmonization (ICH), the Canadian regulator Health Canada together with the Swiss regulator Swissmedic are now standing regulatory members of ICH (formerly they were observers). Since its inception ICH had its bi-annual meetings circulating only between ICH founding member countries/regions - European Union, Japan and the United States. This year for the first time, ICH met outside founding member locations in Montreal, Canada on 27 May to 1 June 2017. In the new ICH, since June 2016, CIOMS has an official ICH observer status. The Secretary-General of CIOMS, Dr Lembit Rägo (LR), participated in the ICH Assembly in Montreal. A major news item was that the ICH Assembly approved the China Food and Drug Administration (CFDA) as a new Regulatory Member, and Pharmaceutical Inspection Co-operation Scheme (PIC/S) as a new Observer. With these new parties, there are now 14 members and 23 observers (see more details at www.ich.org). It was also agreed that Paediatric medicines and modernisation of good clinical practice (GCP) principles will be new topics for ICH.

The ICH Assembly agreed to begin work on two new topics. The new Working Group will further advance the use of paediatric extrapolation, which is the focus of the new ICH E11(R1) guideline currently under development. The aim is to provide guidance on incorporating extrapolation methods in an overall approach to paediatric medicinal product development. A harmonised approach to the appropriate use of extrapolation from adult data will improve the speed of access to new drugs for children. The second new topic is the revision of the 1997 ICH E8 guideline on general considerations for clinical trials. This is part of the strategic 'GCP renovation' announced at the November 2016 Osaka meeting. The revision will look at study design, planning and conduct, with a focus on identifying and supporting a basic set of critical-to-quality factors. Improved clinical trials contribute to public health by generating better evidence to inform regulatory decision-making, by avoiding the need for repeat trials and unnecessary exposure for trial participants, and helping to avoid discontinuation of promising development programs.

Two guidelines reached final status (Step 4) and were adopted by the Assembly. The M7(R1) addendum to the guideline on Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk provides a list of compounds for which mutagenic potential and the threshold of toxicological concern have been established. The update of the Questions and Answers on the implementation guide package of the guideline E2B(R3): Electronic Transmission of Individual Case Safety Reports. In addition, the Assembly made some revisions to the Articles of Association and rules of procedure. With a growing number of members and observers, the changes include caps on the size of Expert Working Groups to ensure they remain a manageable size and revisions to the criteria for an international organisation to become an Observer. ICH aims to attract and engage with all organisations that are impacted by ICH harmonisation and that can bring value to its work; the revised criteria try to make sure that ICH is engaging with relevant global umbrella organisations at the highest level of representation. In Montreal, the Assembly also welcomed Standing Observer IFPMA's plan to initially use its seat on ICH Working Groups to facilitate the participation of IFPMA National Association experts in Working Groups. The next ICH meeting will take place 11–16 November 2017 in Geneva, Switzerland.

Digital Citizen, Digital Patient

The Secretary-General of CIOMS, Dr Lembit Rägo (LR), participated at EMIF (European Medical Information Framework – more at http://www.emif.eu/): "Digital Citizen, Digital Patient" conference on 28-29th June in Tallinn, Estonia. EMIF is an European Innovative Medicines Initiative (IMI) Project. The meeting was attended by representatives of the European Commission, Estonian Government, Patient Organizations, Academia and Industry. LR presented in the session "Incentivising the Sharing of Stakeholder Health Data – What works?". As Estonia is well advanced in digital governance in general and in digital health in particular, it has made e-health its priority during the just started EU Presidency.

Seventh UNESCO NGO Forum

Dr Lembit Rägo also participated in the 7th UNESCO Nongovernmental Organizations (NGO) Forum dedicated to Youth and their Social Input Organized

in partnership with the MiSK Foundation Riyadh, Kingdom of Saudi Arabia, 3–4 May 2017. More information is available about the Forum at http://unescongoforum2017.com/

Old CIOMS Publications available again

Two CIOMS publications that are out of print were recently made available digitally on the CIOMS online bookshop and have been in high demand. They are:

- Guidelines for Preparing Core Clinical-Safety Information on Drugs – Report of CIOMS Working Group III (1995)
- Guidelines for Preparing Core Clinical-Safety Information on Drugs Second Edition – Report of CIOMS Working Groups III and V Including New Proposals for Investigator's Brochures (1999)

In Remembrance: Amanda Owden

19 November 1956 – 5 June 2017

The CIOMS Secretariat is sad to announce the passing away, on 5 June 2017, of a former staff member, Amanda Owden, who worked for 12 years with great distinction as the Administrative Officer. During this period, she was the right-hand staff member for three Secretaries-General of CIOMS, as well as for two Presidents of CIOMS. Her tasks included making the necessary financial and travel arrangements for meetings held in different parts of the world, as well as for the actual convening of meetings. She displayed an innate skill in interacting with the numerous distinguished medical and scientific experts serving on diverse CIOMS Working Groups. She was always ready to provide information and advice – with a personal touch. She was scrupulously efficient in keeping the CIOMS accounts. One former Secretary-General (Dr Gunilla Sjölin-Forsberg) recalls how Amanda initiated her into Genevese customs and holidays (and bought her the traditional chocolate marmite one December day – which commemorates events that took place in Geneva in December 1602!).

Amanda was born in Aldershot, England, on 9 November 1956, and spent three years of her childhood in Kenya (where her father, a British Army Captain, had been posted), and was later sent to a boarding-school in Littlehampton, England. Later, she spent several years in Paris, where – in addition to professional work – she studied at the Sorbonne, and received the Diploma in French Language and Civilization. She lived in New York from 1982 to 1984, where she married a United Nations interpreter, Mr Jamal Challali, whom she had met in Paris (and to whom CIOMS extends its profound condolences). Her husband was subsequently posted to the UN Office in Bangkok, and a son, Julian, was born there in 1987. Amanda worked in Bangkok, first for the Southeast Asian Fisheries Development Center and subsequently at the United Nations Economic and Social Commission for Asia and the Pacific (better known as ESCAP). In 1994, Mr Challali was transferred to the UN Office in Geneva, and they made their home here. Prior to joining CIOMS in 2002, Amanda worked in various administrative, translation, and editing posts in diverse UN offices and nongovernmental organizations, including the Quaker UN Office (for a 4-year period).

One of Amanda's colleagues, Ms Karin Holm, sums up her character in moving terms: "Amanda leaves a legacy of compassion in her wake that will guide and nurture her family and friends. We may grieve her departure, but we can rejoice in having known her and felt connected with her. She was a beautiful person". Ms Holm adds: "Amanda had a very engaging way of connecting with people and an incredible memory for details about others' lives. Many people have mentioned the pleasant way she would chat with colleagues and external contacts, always giving information and advice with a personal touch so that everyone felt embraced."

RECENT ARTICLES ABOUT CIOMS

Where available, articles about CIOMS can be accessed through our website at : www.cioms.ch/cioms-in-the-media/

Guide to active vaccine safety surveillance: Report of CIOMS working group on vaccine safety - executive summary.

Heininger U, Holm K, Caplanusi I, Bailey SR; CIOMS Working Group on Vaccine Safety. *Vaccine*. 2017 Jul 13;35(32):3917-3921.

CIOMS guidelines remain conservative about vulnerability and social justice

Calvin Wai-Loon Ho. *Indian J Med Ethics*. 2017 published online Jun 20

Patterns of use and impact of standardised MedDRA query analyses on the safety evaluation and review of new drug and biologics license applications.

Chang LC, Mahmood R, Qureshi S, Breder CD. PLoS One. 2017 Jun 1;12(6):e0178104. doi: 10.1371/journal.pone.0178104.

Critical analysis of the Council for International Organizations of Medical Sciences 2016 International Guidelines for health-related research involving humans.

Kottow Lang MH. *Medwave*. 2017 May 15;17(4):e6956

Schuklenk's critique of the CIOMS guidelines: All procedure, no substance.

Macklin R. *Indian J Med Ethics*. 2017 Mar 29;-(-):1-3.

Research ethics for a globalised world: the revised CIOMS international guidelines.

Ehni HJ, Wiesing U. *Indian J Med Ethics*. 2017 Mar 7;-(-):1-4.

Revised CIOMS research ethics guidance: on the importance of process for credibility.

Schuklenk U. *Indian J Med Ethics*. 2017 Mar 7;-(-):1-4.

Revised CIOMS International Ethical Guidelines for Health-Related Research Involving Humans.

Van Delden JJ, van der Graaf R. *JAMA*. 2017 Jan 10;317(2):135-136.

CIOMS Publications in e-bookshop

Several CIOMS publications in both hardcopy and PDF format are available for free and can be ordered or downloaded directly from the online bookshop at: **https://cioms.ch/product-category/free-publications/** Other titles can be purchased with discounts when you buy 2 or more hardcopies of the same title.

CIOMS SECRETARIAT

Secretary-General

Dr Lembit Rägo

Tel: +41 22 791 6410

Administrative Assistant

Ms Sue Le Roux

Tel: +41 22 791 6439

UPCOMING MEETINGS

12th Meeting of MedDRA Implementation Working Group, Geneva, Switzerland

27-28 September 2017

2nd Meeting of CIOMS Working Group on Drug-induced Liver Injury (DILI), Malaga, Spain

14-15 November 2017

84th CIOMS Executive Committee Meeting, Geneva, Switzerland

28 November 2017